Bevacizumab therapy for retinopathy of prematurity
- Conditions
- Intraocular neovascularization
- Registration Number
- JPRN-jRCTs051180175
- Lead Sponsor
- Ohnaka Masayuki
- Brief Summary
Bevacizumab therapy was considered to be a safe and effective treatment for retinopathy of prematurity, because there were no complications after the treatment and the timing of retinal photocoagulation was able to push off.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 21
1, Patients with diseases in which intraocular neovascular vessels do not disappear or reappeared after conventional therapy such as retinal photocoagulation
2, Retinopathy of prematurity, regardless of treatment, is zone I disease, zone II disease with stage 2+ or 3+, and aggressive posterior retinopathy of prematurity in the international classification
3, From 2 weeks old to 12 years old
4, Written informed consent by parents
1, Patients with infarct disease, heart failure with poor control, hypertension, renal failure, abnormal blood coagulation ability, gastrointestinal ulcer
2, Patients who need to take other treatment priorities due to poor general condition
3. Patients who judged that neonatal specialists, pediatricians or the researcher are inappropriate as research subjects
4. Patients participating in other studies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of retinal detachment after treatment
- Secondary Outcome Measures
Name Time Method Incidence of cataract after treatment<br>Timing of retinal photocoagulation after treatment